AOD-9604 Dosage: What the Evidence Says (2026)
Not FDA-approved
Growth hormone fragment developed as an obesity pill. Failed phase 2b; development stopped in 2007.
Also called: hGH fragment 176-191
Regulatory status (US)
Not approved by the FDA for any use. Its nomination for pharmacy compounding was withdrawn, so it is on none of FDA's 503A lists and is not covered by the October 2026 HHS draft policy. In practice that means no legal US source for human use.
What it is
A modified fragment of the end of the human growth hormone molecule, developed for fat loss.
Dosage
AOD-9604 reconstitution calculator
Enter your vial and your prescribed dose to see the units on a U-100 syringe.
What human studies show
- Tested as a pill (1 to 30 mg a day) in Australia. The larger 24-week phase 2b trial did not beat placebo, and obesity development ended in 2007.
- No human data for injection.
Safety
- No approved dose for any use.
Questions
- Is AOD-9604 FDA-approved?
- Not approved by the FDA for any use. Its nomination for pharmacy compounding was withdrawn, so it is on none of FDA's 503A lists and is not covered by the October 2026 HHS draft policy. In practice that means no legal US source for human use.
- What dose of AOD-9604 has been studied?
- There is no established human dose. Tested as a pill (1 to 30 mg a day) in Australia. The larger 24-week phase 2b trial did not beat placebo, and obesity development ended in 2007. No human data for injection.
- How many units is my AOD-9604 dose?
- Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.
Related
The first 29 amino acids of GHRH. Former brand Geref was withdrawn in 2009; no product is marketed today.
BPC-15715-amino-acid peptide studied mostly in animals. Not approved; no established human dose.
TB-500 (thymosin beta-4)Name used for thymosin beta-4 and for a 7-amino-acid fragment of it. Not approved; no human dose data for the fragment.
GHK-Cu (copper peptide)Copper-binding tripeptide used in skin care. Topical studies only; no human injection data.
Sources
- BioWorld: Development of AOD-9604 in obesity terminated after phase IIb
- ANZCTR ACTRN12605000067673: AOD-9604 phase 2b trial
- FDA: 503A bulk drug substance categories (updated May 14, 2026, PDF)
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
Last checked 2026-11-16. How we pick and check sources: methodology.